



## UNAUDITED RESULTS FOR THE PERIOD ENDED JUNE 30, 2016

### INTRAVENOUS INFUSIONS LTD.

#### KEY FINANCIAL HIGHLIGHTS

	JUNE 2016	JUNE 2015
	UNAUDITED GH¢	UNAUDITED GH¢
Revenue	4,781,354	2,923,740
Gross Profit	2,225,993	1,179,230
Foreign Exchange Loss	86,036	1,060,400
Finance Costs	220,834	261,834
Operating Profit/(Loss)	817,815	(1,008,774)
Net Profit/(Loss) before tax	596,981	(1,270,608)



**INTRAVENOUS INFUSIONS LTD.**

**UNAUDITED STATEMENT OF PROFIT OR LOSS AND OTHER  
COMPREHENSIVE INCOME FOR THE PERIOD ENDED JUNE 30, 2016**

	<b>JUNE 2016</b>	<b>JUNE 2015</b>
	<b>UNAUDITED GH¢</b>	<b>UNAUDITED GH¢</b>
Revenue	4,781,354	2,923,740
Cost of operations	<u>(2,555,361)</u>	<u>(1,744,510)</u>
Gross profit	2,225,993	1,179,230
Other income	3,484	17,770
Operating and other expenses	<u>(1,411,662)</u>	<u>(2,205,774)</u>
Profit before finance cost and tax	817,815	(1,008,774)
Finance cost	<u>(220,834)</u>	<u>(261,834)</u>
Profit before tax	596,981	(1,270,608)
Income tax expense	<u>(111,934)</u>	-
Deferred tax asset	-	-
Profit for the year	485,047	(1,270,608)
<b>Other Comprehensive income:</b>		
Total comprehensive income	485,047	(1,270,608)



**INTRAVENOUS INFUSIONS LTD.**

**UNAUDITED STATEMENT OF FINANCIAL POSITION AS AT JUNE 30, 2016**

	<b>JUNE 2016</b>	<b>JUNE 2015</b>
	<b>UNAUDITED</b>	<b>UNAUDITED</b>
	<b>GH¢</b>	<b>GH¢</b>
<b>ASSETS</b>		
<b>Non-current assets</b>		
Property, plant and equipment	<u>3,886,502</u>	<u>3,702,114</u>
Total non-current asset	<u>3,886,502</u>	<u>3,702,114</u>
<b>Current assets</b>		
Inventory	1,576,970	1,705,220
Trade and other receivables	6,360,292	4,682,026
Cash	244,182	84,815
Current tax	<u>69,824</u>	<u>118,556</u>
Total current asset	<u>8,251,268</u>	<u>6,590,617</u>
<b>Total assets</b>	<u>12,137,770</u>	<u>10,292,731</u>
<b>Equity</b>		
Stated capital	7,213,184	570,520
Retained earnings	(2,671,812)	(3,285,904)
Capital surplus	<u>2,468,400</u>	<u>2,468,400</u>
Total equity	<u>7,009,772</u>	<u>(246,984)</u>
<b>Non-Current Liability</b>		
Employee Benefit obligation	1,071,660	903,183
Deferred tax liabilities	<u>616,689</u>	<u>652,217</u>
Total non-Current Liability	<u>1,688,349</u>	<u>1,555,400</u>
<b>Current liabilities</b>		
Borrowings	1,815,029	1,855,105
Trade payables	1,624,620	7,129,210
Current tax	-	-
Total current liabilities	<u>3,439,649</u>	<u>8,984,315</u>
Total Liability	<u>5,127,998</u>	<u>10,539,715</u>
<b>Total Liabilities and equity</b>	<u>12,137,770</u>	<u>10,292,731</u>



**INTRAVENOUS INFUSIONS LTD.**

**UNAUDITED STATEMENT OF CHANGES IN EQUITY**

	<b>Stated capital</b>	<b>Income surplus</b>	<b>Capital surplus</b>	<b>Total</b>
Balance at 1 Jan 2016	7,213,184	(3,156,859)	2,468,400	6,524,725
cash from share issue	-			-
Profit/(Loss) for the year	-----	<u>485,047</u>	-----	<u>485,047</u>
At 31 December 2015	<u>7,213,184</u>	<u>(2,671,812)</u>	<u>2,468,400</u>	<u>7,009,772</u>



**INTRAVENOUS INFUSIONS LTD.**

**UNAUDITED STATEMENT OF CASH FLOWS  
FOR THE PERIOD ENDED JUNE 30, 2016**

	<b>JUNE 2016 UNAUDITED GH¢</b>	<b>JUNE 2015 UNAUDITED GH¢</b>
<b>Operating activities</b>		
Profit before tax	596,981	(1,270,608)
<b>Adjustments for non-cash income and expenses:</b>		
Depreciation of property, plant and equipment	107,967	123,927
Employee Benefits Costs	<u>50,000</u>	-
<b>Cash flow included in operating activities:</b>	<b>754,948</b>	<b>(1,146,681)</b>
Changes in operating assets and liabilities		
Decrease (increase) in trade and other receivables	(1,188,681)	(415,552)
Increase/ decrease) in trade payables	(3,914,125)	1,202,931
Purchase of /inventory	<u>(322,559)</u>	<u>(645,546)</u>
<b>Cash flow from operating activities</b>	<b>(4,670,417)</b>	<b>(1,004,848)</b>
Tax paid	<u>(21,266)</u>	<u>(2,898)</u>
<b>Net cash from operating activities</b>	<b>(4,691,683)</b>	<b>(1,007,746)</b>
<b>Cash flows from investing activities</b>		
Proceeds from sale of equipment	-	-
Purchases of equipment	<u>(361,382)</u>	<u>(30,977)</u>
<b>Net cash used in investing activities</b>	<b>(361,382)</b>	<b>(30,977)</b>
<b>Cash flows from financing activities</b>		
Increase in borrowings	1,815,029	890,240
Cash from share issue	-	-
<b>Net cash used in financing activities</b>	<b>1,815,029</b>	<b>890,240</b>
<b>Net increase decrease) in cash and cash equivalents</b>	<b>(3,238,036)</b>	<b>(148,483)</b>
Cash and cash equivalents at beginning of year	<u>3,482,218</u>	<u>233,298</u>
<b>Cash and cash equivalents at end of year</b>	<b><u>244,182</u></b>	<b><u>84,815</u></b>



To the above accounts have been prepared in accordance with International Financial Reporting Standards and in compliance with the companies code 1963, (Act 179).

Best of our knowledge the Financial Statements do not contain any untrue statements or misleading facts and no material facts have been omitted

LEON APPENTENG  
DIRECTOR

ISAAC OSEI  
CHAIRMAN